MaaT Pharma Faces Challenges in Q1 2026

MaaT Pharma reported a "negative trend" opinion from the European Medicines Agency (EMA) regarding its Marketing Authorization Application for MaaT013 (Xervyteg®). A formal vote by the EMA's Committee for Medicinal Products is anticipated in June, with a planned re-examination by the company. Despite this, MaaT Pharma showcased promising trial data at the EBMT 2026 congress.

Revenues for Q1 2026 amounted to €0.8 million, largely from an Early Access Program transitioned to Clinigen. The firm's cash position was €18.1 million as of March 31, 2026, with operations funded until November 2026. Financial discipline and strategic partnerships remain central as the company navigates regulatory hurdles.

MaaT Pharma is advancing its pipeline in hemato-oncology and immuno-oncology, with ongoing trials like PHOEBUS and IMMUNOLIFE. In the U.S., exploration continues for MaaT013, relying heavily on funding and regulatory approvals.